Governance Classic Home
GlaxoSmithKline Pharmaceuticals LtdPharmaceuticalsINE159A01016Consolidated₹2838.80+38.90 (+1.39%)Jun-26
Valuation
Market Cap₹48.09K Cr
TTM PE45.78x
Forward PE45.36x
PEG14.49
Book Value₹133.85
P/B21.21x
TTM EPS₹62.01
Fwd EPS₹62.59
TTM Revenue₹3.95K Cr
TTM PAT₹1.07K Cr
TTM EBITDA₹1.35K Cr
TTM EBIT₹1.29K Cr
Last Qtr PAT₹237.18 Cr
Last Qtr EBITDA₹295.50 Cr
Last Qtr EBIT₹279.66 Cr
Profitability
ROE47.11%
ROCE63.65%
TTM NPM27.01%
TTM EBITDA %34.22%
Curr OPM24.15%
Last OPM26.94%
Curr NPM—
Last NPM—
Curr EPS₹14.00
Last EPS₹16.40
Balance sheet
Equity₹169.41 Cr
Reserve₹2.10K Cr
Total Debt₹15.00 Cr
D/E0.01x
Interest %0.41%
Curr Interest₹0.97 Cr
Price / range
Close₹2838.80
vs 52W High—
vs 52W Low—
MA50—
MA200—
Returns
1D+1.39%
1W+0.37%
1M-1.34%
3M+25.27%
6M+16.58%
1Y+3.25%
2Y+1.56%
3Y+78.45%
5Y+84.46%
Diwali+15.62%
Sector peers — Pharmaceuticals
CompanyCloseMkt CapTTM P/EROE
SUNPHARMA1837.30₹4.41L Cr36.4514.50%
DIVISLAB9375.00₹2.49L Cr85.0617.45%
TORNTPHARM4840.00₹1.84L Cr77.3225.70%
ZYDUSLIFE1160.00₹1.16L Cr25.8516.94%
CIPLA1394.50₹1.13L Cr33.419.75%
LAURUSLABS1954.00₹1.06L Cr96.4520.58%
AUROPHARMA1734.00₹99.77K Cr27.099.79%
DRREDDY1185.00₹98.91K Cr30.638.40%

Financial Results

Quarterly and yearly P&L · YoY % on Revenue, Total Income, Expenditure, EBITDA, EBIT, PBT, Net Profit and EPS

Standalone

16 lines · 6 periods
MetricJun-26Mar-26Dec-25Sep-25Jun-25FY25-26
Revenue924.42+14.9%989.151,022.59973.63804.833,790.20
Other Income61.6335.7131.8231.2743.76142.56
Total Income986.05+16.2%1,024.861,054.411,004.90848.593,932.76
Interest0.970.611.190.510.422.73
Expenditure-648.07-13.7%-655.74-676.52-656.89-570.02-2,559.17
PBDT000000
EBITDA293.16+16.9%347.19367.58334.68250.751,300.20
Depreciation-15.84-13.17-20.32-17.43-15.52-66.44
EBIT277.32+17.9%334.02347.26317.25235.231,233.76
PBT337.98+21.3%369.12377.89350.65278.571,376.23
Tax-84.65-94.18-100.71-95.65-73.87-364.41
Equity169.41169.41169.410169.41169.41
OPM34.2836.0235.8436.0132.8334.99
Net Profit253.33+23.8%274.94277.18255204.701,011.82
NPM25.6926.8326.2926.1924.1225.73
EPS14.95+23.8%16.2316.3614.9212.0859

Yearly results

Last 6 financial years · YoY % vs previous FY

Yearly

17 lines · 6 years
MetricFY 25-26FY 24-25FY 23-24FY 22-23FY 21-22FY 20-21
Revenue3,790.20+1.8%3,723.49+9.3%3,407.25+5.9%3,216.340.0%3,217.51+0.7%3,193.73
Other Income142.56142.56123.48101.5276.22110.19
Total Income3,932.76+1.7%3,866.05+9.5%3,530.73+6.4%3,317.86+0.7%3,293.73-0.3%3,303.92
Expenditure-2,559.17+2.4%-2,622.30-1.7%-2,578.08-3.8%-2,484.51+1.9%-2,531.86+1.9%-2,581.59
Interest-2.73-1.31-1.80-1.81-1.99-3.53
PBDT000000
EBITDA1,300.20+11.2%1,169.29+29.8%900.65+12.7%799.41+5.8%755.83+8.8%694.95
Depreciation-66.44-66.79-69.68-65.77-68.19-79.28
EBIT1,233.76+11.9%1,102.50+32.7%830.97+13.3%733.64+6.7%687.64+11.7%615.67
PBT1,376.23+10.2%1,248.44+54.3%809.04-2.8%832.38+7.6%773.45+40.7%549.73
Tax-364.41-329.38-224.35-227.68-396.87-192.17
Equity169.41169.410000
OPM (%)34.9932.2923.0025.0023.0017.00
Net Profit1,011.82+10.1%919.06+57.2%584.69-3.8%607.75-64.0%1,690.53+372.8%357.56
NPM (%)25.7323.7717.0018.0051.0011.00
EPS (Rs)59+9.2%54.01+56.5%34.51-3.8%35.88-64.0%99.79+372.7%21.11
CEPS5954.2434.5135.8899.7921.11

Consolidated

16 lines · 6 periods
MetricJun-26Mar-26Dec-25Sep-25Jun-25FY25-26
Revenue938.44+16.6%995.301,041.26979.94805.173,821.67
Other Income43.7635.9532.1233.5743.72145.36
Total Income982.20+15.7%1,031.251,073.381,013.51848.893,967.03
Interest0.970.611.190.510.422.73
Expenditure-659.75-15.8%-658.15-691.43-662.15-569.91-2,581.64
PBDT000000
EBITDA295.50+17.6%350.93371.34335.73251.201,309.20
Depreciation-15.84-13.17-20.32-17.43-15.52-66.44
EBIT279.66+18.7%337.76351.02318.30235.681,242.76
PBT322.45+15.6%373.10399.93354278.981,406.01
Tax-85.27-95.24-104.31-96.51-73.97-370.03
Equity169.41169.41169.410169.41169.41
OPM32.8336.1837.2634.9332.8635.44
Net Profit237.18+15.7%277.86295.62257.49205.011,035.98
NPM24.1526.9427.5425.4124.1526.11
EPS14+15.7%16.4016.5415.0712.1054.52

Yearly results

Last 6 financial years · YoY % vs previous FY

Yearly

17 lines · 6 years
MetricFY 25-26FY 24-25FY 23-24FY 22-23FY 21-22FY 20-21
Revenue3,821.67+1.9%3,749.21+8.6%3,453.71+6.2%3,251.72-0.8%3,278.03+2.5%3,198.86
Other Income145.36145.93122.59100.6675.78110.58
Total Income3,967.03+1.8%3,895.14+8.9%3,576.30+6.7%3,352.380.0%3,353.81+1.3%3,309.44
Expenditure-2,581.64+2.2%-2,639.95-0.9%-2,616.50-4.0%-2,515.01+2.8%-2,586.34+0.0%-2,586.34
Interest-2.73-1.31-1.80-1.81-2-3.53
PBDT000000
EBITDA1,309.20+11.2%1,177.36+29.6%908.69+13.0%804.29+5.6%761.88+9.6%695.33
Depreciation-66.44-66.79-69.68-65.77-68.19-79.28
EBIT1,242.76+11.9%1,110.57+32.4%839.01+13.6%738.52+6.5%693.69+12.6%616.05
PBT1,406.01+11.6%1,259.88+54.4%816.19-2.4%836.40+7.4%779.05+41.5%550.50
Tax-370.03-332.30-226.23-228.76-398.28-192.35
Equity169.41169.410000
OPM (%)35.4432.3422.8224.9523.2316.63
Net Profit1,035.98+11.7%927.58+57.2%589.96-3.4%610.69-64.0%1,694.72+373.2%358.15
NPM (%)26.1123.8116.5018.2250.5310.82
EPS (Rs)54.52+0.0%54.52+56.5%34.83-3.4%36.05-64.0%100.04+373.2%21.14
CEPS54.7654.7634.8336.05100.0421.14

Corporate Actions

Dividends, bonus issues, and stock splits

Dividend

22
YearTypeAmountEx-Date
2026Final Dividend5729 May 2026
2025Final Dividend4230 May 2025
2025Interim Dividend1207 Nov 2024
2024Final Dividend3231 May 2024
2023Final Dividend3230 Jun 2023
2022Final Dividend3007 Jul 2022
2022Special Dividend6007 Jul 2022
2021Final Dividend3019 Jul 2021
2020Final Dividend2017 Jul 2020
2020Special Dividend2017 Jul 2020
2019Final Dividend2011 Jul 2019
2018Final Dividend3513 Jul 2018
2017Final Dividend3014 Jul 2017
2016Final Dividend5015 Jul 2016
2015Final Dividend62.523 Jul 2015
2014Final Dividend5003 Apr 2014
2013Final Dividend5004 Apr 2013
2012Final Dividend4529 Mar 2012
2011Final Dividend4014 Mar 2011
2010Final Dividend3010 Mar 2010
2009Final Dividend4018 Mar 2009
2008Final Dividend3602 Apr 2008

Bonus

1
YearRatioEx-Date
20181:111 Sep 2018

Split

0

No split history.

Loading company dashboard...
Fetching ratios, charts, and peers